| Primary |
| Chemotherapy |
45.1% |
| Product Used For Unknown Indication |
14.5% |
| Breast Cancer |
12.4% |
| Neutropenia |
4.6% |
| Drug Use For Unknown Indication |
4.4% |
| B-cell Lymphoma |
3.7% |
| Non-hodgkin's Lymphoma |
2.4% |
| Prophylaxis |
2.3% |
| Diffuse Large B-cell Lymphoma |
2.2% |
| Lymphoma |
2.0% |
| Hodgkin's Disease |
1.3% |
| Pain |
0.8% |
| Neoplasm Malignant |
0.8% |
| Hypertension |
0.7% |
| Chronic Lymphocytic Leukaemia |
0.7% |
| Ovarian Cancer |
0.6% |
| Lung Neoplasm Malignant |
0.5% |
| Testis Cancer |
0.4% |
| Acute Myeloid Leukaemia |
0.4% |
| Malignant Lymphoid Neoplasm |
0.4% |
|
| Febrile Neutropenia |
16.2% |
| Neutropenia |
10.5% |
| Pyrexia |
7.9% |
| Death |
7.1% |
| White Blood Cell Count Decreased |
6.6% |
| Drug Ineffective |
6.1% |
| Bone Pain |
5.7% |
| White Blood Cell Count Increased |
5.3% |
| Vomiting |
4.4% |
| Pain |
3.8% |
| Thrombocytopenia |
3.8% |
| Therapeutic Response Decreased |
3.4% |
| Urticaria |
3.2% |
| Rash |
2.8% |
| Neutropenic Sepsis |
2.5% |
| Sepsis |
2.5% |
| Neutrophil Count Decreased |
2.2% |
| Leukocytosis |
2.2% |
| Back Pain |
2.1% |
| Dyspnoea |
1.8% |
|
| Secondary |
| Breast Cancer |
18.4% |
| Diffuse Large B-cell Lymphoma |
13.8% |
| Product Used For Unknown Indication |
11.7% |
| Chemotherapy |
10.9% |
| Drug Use For Unknown Indication |
9.2% |
| Non-hodgkin's Lymphoma |
5.9% |
| Mantle Cell Lymphoma |
5.7% |
| B-cell Lymphoma |
5.1% |
| Prophylaxis |
3.2% |
| Premedication |
2.4% |
| Neutropenia |
2.4% |
| Chronic Lymphocytic Leukaemia |
2.2% |
| Hypertension |
1.5% |
| Nausea |
1.3% |
| Malignant Lymphoid Neoplasm |
1.2% |
| Hodgkin's Disease |
1.2% |
| Glioblastoma Multiforme |
1.1% |
| Lymphoma |
1.0% |
| Anaemia Of Malignant Disease |
0.9% |
| Pain |
0.9% |
|
| Febrile Neutropenia |
14.7% |
| Vomiting |
13.1% |
| White Blood Cell Count Decreased |
12.0% |
| Pyrexia |
8.5% |
| Thrombocytopenia |
5.8% |
| Death |
5.4% |
| Neutropenia |
4.3% |
| Bone Pain |
3.8% |
| Dyspnoea |
3.4% |
| Weight Decreased |
3.4% |
| Septic Shock |
3.2% |
| Neutrophil Count Decreased |
2.9% |
| Pneumonia |
2.9% |
| Pulmonary Embolism |
2.7% |
| Pancytopenia |
2.6% |
| Fatigue |
2.4% |
| Malaise |
2.4% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
2.2% |
| Petechiae |
2.2% |
| Sepsis |
2.2% |
|
| Concomitant |
| Drug Use For Unknown Indication |
15.3% |
| Breast Cancer |
14.7% |
| Product Used For Unknown Indication |
12.2% |
| Prophylaxis |
7.0% |
| Diffuse Large B-cell Lymphoma |
5.1% |
| Nausea |
4.9% |
| Non-small Cell Lung Cancer |
4.8% |
| Hypertension |
4.5% |
| Premedication |
4.2% |
| Pain |
4.0% |
| Non-hodgkin's Lymphoma |
3.0% |
| B-cell Lymphoma |
2.9% |
| Prostate Cancer |
2.9% |
| Breast Cancer Metastatic |
2.7% |
| Multiple Myeloma |
2.5% |
| Neutropenia |
2.1% |
| Constipation |
2.0% |
| Chronic Lymphocytic Leukaemia |
1.9% |
| Chemotherapy |
1.7% |
| Mantle Cell Lymphoma |
1.6% |
|
| White Blood Cell Count Decreased |
11.4% |
| Thrombocytopenia |
9.7% |
| Vomiting |
9.2% |
| Pyrexia |
7.7% |
| Sepsis |
5.7% |
| Pneumonia |
5.4% |
| Neutropenia |
5.1% |
| Febrile Neutropenia |
4.8% |
| Weight Decreased |
4.6% |
| Weight Increased |
4.6% |
| Death |
4.4% |
| White Blood Cell Count Increased |
3.9% |
| Pancytopenia |
3.6% |
| Respiratory Failure |
3.5% |
| Urinary Tract Infection |
3.5% |
| Pain |
2.8% |
| Septic Shock |
2.6% |
| Tachycardia |
2.6% |
| Renal Failure Acute |
2.5% |
| Wound Infection Staphylococcal |
2.5% |
|
| Interacting |
| Drug Use For Unknown Indication |
35.1% |
| Product Used For Unknown Indication |
28.6% |
| Diffuse Large B-cell Lymphoma |
10.4% |
| Pneumonia Bacterial |
10.4% |
| Hodgkin's Disease |
5.2% |
| Hairy Cell Leukaemia |
3.9% |
| Neutropenia |
3.9% |
| Chemotherapy |
2.6% |
|
| Drug Interaction |
33.3% |
| Pneumonitis |
33.3% |
| Monocyte Count Decreased |
25.0% |
| Pulmonary Fibrosis |
8.3% |
|
